Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...

Atalanta Therapeutics has technology that delivers RNA interference therapies into the CNS. The startup has spent the past four years quietly working on its technology and potential drugs.

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Guggenheim SMID Cap Biotech Conference Date: February 5, 2025 Location: New York, NY Format: 1x1 Meetings Oppenheimer 35th Annual Healthcare Life Sciences Conference (being held virtually) Date: ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Atalanta Therapeutics Inc. has completed a $97 million series B financing to support its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease toward ...